<DOC>
	<DOCNO>NCT01875393</DOCNO>
	<brief_summary>The aim study confirm Efficacy , Safety Quality Life TOOKAD® Soluble VTP localize prostate cancer patient .</brief_summary>
	<brief_title>Efficacy , Safety Quality Life After TOOKAD® Soluble VTP Localized Prostate Cancer</brief_title>
	<detailed_description>The study design multicenter , single-arm , open label , 12 month follow-up clinical trial . Men localize prostate cancer treat TOOKAD® Soluble VTP general anesthesia . Patients followed-up 12 month patient questionnaire QoL , erectile urinary function , clinical evaluation study visit 1 , 3 , 6 12 month , Prostate Specific Antigen ( PSA ) test 3 , 6 12 month . In addition , biopsy 6 month ( ± 2 ) 12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically proven localized prostate carcinoma diagnose use prostate biopsy showing : Gleason 3+3 prostate Gleason 3+4 prostate adenocarcinoma acceptable provide present 2 core 50 % cancer core . Clinical stage cT2a N0/Nx M0/Mx . Serum prostatespecific antigen ( PSA ) ˂ 20ng/ml Prostate volume ≥ 25 cc ≤ 70 cc . Male subject age 18 year old . Signed Informed Consent Form patient . Unwillingness accept treatment . Any prior current treatment prostate cancer , include surgery , radiation therapy ( external brachytherapy ) chemotherapy . Any surgical intervention benign prostatic hypertrophy . Any condition history illness surgery may pose additional risk men undergo VTP procedure . Life expectancy le 10 year . Participation another clinical study involve investigational product within 1 month study entry . Subject unable understand patient 's informed consent document , give consent voluntarily complete study task , especially unable understand fulfill healthrelated QoL questionnaire . Subject custody residence nursing home rehabilitation facility . Any condition history active rectal inflammatory bowel disease factor may increase risk fistula formation ; Any hormonal manipulation ( exclude 5alphareductase inhibitor ) alters androgen production use androgen supplement within previous 6 month ; Any history urethral stricture disease ; Any history acute urinary retention within 6 month study entry</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Prostatic Disease</keyword>
	<keyword>Genital Neoplasm , male</keyword>
	<keyword>Urogenital neoplasm</keyword>
	<keyword>Genital disease , male</keyword>
	<keyword>Male urogenital disease</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms site</keyword>
	<keyword>Prostatic neoplasm</keyword>
	<keyword>Carcinoma</keyword>
</DOC>